1069-62-1

Usage

Uses

Used in Pharmaceutical Industry:
(2-Acetyl-4-Methylpentyl)trimethylammonium Iodide is used as an impurity in the production of Tetrabenazine (T284000), an antipsychotic medication. Its presence in the drug may affect the overall efficacy, safety, and pharmacological profile of the medication. As a result, it is crucial to monitor and control the levels of this impurity during the manufacturing process to ensure the quality and effectiveness of the final product.
In the context of its use as an impurity in Tetrabenazine, the compound may have potential implications for the drug's pharmacological actions, side effects, and overall therapeutic profile. Further research and investigation may be necessary to fully understand the role and impact of (2-Acetyl-4-Methylpentyl)trimethylammonium Iodide in the context of antipsychotic medications and their use in treating various psychiatric disorders.

Upstream product

• 91342-74-4 3-[(dimethylamino)methyl]-5-methylhexan-2-one 
• 74-88-4 methyl iodide 
• 86497-40-7 trimethyl-(5-methylhex-2-en-2-yloxy)silane 
• 110-12-3 5-Methyl-2-hexanone 
• 1522-34-5 ethyl 2-acetyl-4-methylpentanoate 

Downstream Products

• 58-46-8 (3R^*,11bR^*)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzoquinolizin-2-one 
• 1221885-59-1 deutetrabenazine 
• 89929-27-1 (+/-)-9,10-dihydroxy-3c-isobutyl-(11br)-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one 
• 1187-87-7 5-methyl-3-methylidenehexan-2-one 
• 1065193-59-0 (2R,3R,11bR)-3-isobutyl-10-methoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-2,9-diol 
• 7744-58-3 9-(benzyloxy)-3-isobutyl-10-methoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one 
• 89929-27-1 2-Oxo-3-isobutyl-9,10-dihydroxy-1,2,3,4,6,7-hexahydro-11bH-benzochinolizin 
• 718635-93-9 tetrabenazine 

Relevant academic research and scientific papers

Real-Time Monitoring of Solid-Liquid Slurries: Optimized Synthesis of Tetrabenazine

Solid-liquid slurries are vital and increasingly prevalent in the pharmaceutical and chemical industries. Despite the importance of these heterogeneous systems, process control and optimization are fundamentally hindered by a lack of compatible real-time analytical techniques. We present herein an online HPLC monitoring platform enabling access to real-time compositional information on slurries. We demonstrate the system by investigating the heterogeneous synthesis reaction of tetrabenazine. Furthermore, we integrated our online HPLC platform with the orthogonal monitoring techniques of a pH probe and a microscopic imaging probe to provide additional mechanistic insight. These combined insights enable the optimization of tetrabenazine synthesis in terms of reaction time, byproduct formation, and diastereomeric purity of the final product.

The synthesis of precursor of FP- (+) DTBZ

A synthetic route to the precursor of FP- (+) DTBZ was disclosed, in which 3-hydroxy-4-methoxybenzaldehyde was employed as a starting material. In the method, the benzyl-protecting protocol and the in-situ Diels-Alder reaction made the procedure more practical because of the mild conditions for selectively deprotection and the accelerated reaction process.

BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE

The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.

METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY

Methods for treating abnormal muscular activity are disclosed. The methods may be performed remotely and permit monitoring of a subject outside a healthcare provider's office.

BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. (I)

BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. (Formula (I))

PROCESS FOR PREPARING TETRABENAZINE

A substantially pure crystalline form A of tetrabenazine compound of structural formula I and processes for the preparation thereof is provided.

BENZOQUINOLONE INHIBITORS OF VMAT2

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. Formula (I)